Qlaris Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-08-01
- Employees
- 1
- Market Cap
- -
- Website
- http://qlaris.bio
Clinical Trials
7
Active:0
Completed:6
Trial Phases
1 Phases
Phase 2:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (100.0%)Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Phase 2
Completed
- Conditions
- Ocular Hypertension (OHT)GlaucomaOpen-angle Glaucoma (OAG)
- Interventions
- Drug: QLS-111, 0.015%Drug: QLS-111 vehicle ophthalmic solutionDrug: QLS-111, 0.030%Drug: QLS-111, 0.075%
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06249152
- Locations
- 🇺🇸
Berkeley Eye Center, Houston, Texas, United States
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Phase 2
Not yet recruiting
- Conditions
- Normal Tension Glaucoma (NTG)Low-Tension Glaucoma, Unspecified EyeLow-Tension Glaucoma, BilateralGlaucoma
- Interventions
- Drug: QLS-111 ophthalmic solution (0.015%)Drug: Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06030193
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Phase 2
Completed
- Conditions
- Primary Open Angle Glaucoma of Both EyesPrimary Open Angle Glaucoma (POAG)Ocular Hypertension (OHT)Primary Open-Angle Glaucoma, Unspecified Eye
- Interventions
- Other: QLS-111 ophthalmic vehicle solution
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT06016972
- Locations
- 🇺🇸
Coastal Research Associates, LLC, Roswell, Georgia, United States
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Phase 2
Completed
- Conditions
- Sturge-Weber SyndromeGlaucomaOcular Hypertension
- Interventions
- Drug: QLS-101 ophthalmic solution, 2.0 %
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05495269
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Phase 2
Completed
- Conditions
- Sturge-Weber Syndrome (SWS)GlaucomaGlaucoma CongenitalOcular Hypertension
- Interventions
- Drug: QLS-101ophthalmic solution 1%Drug: QLS-101ophthalmic solution 2%
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Qlaris Bio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04947124
- Locations
- 🇺🇸
Duke Eye Center, Durham, North Carolina, United States
- Prev
- 1
- 2
- Next
News
No news found